Exagen Posts 25-Cent Quarterly Loss as Diagnostics Firm's Results Land
XGN has more than doubled off its 52-week low of $2.59 on elevated volume (2.0× avg).
Summary
Exagen reported a third-quarter loss of 25 cents a share on revenue of $18.4M, up 7% from a year earlier, with the net loss at $6.34M. That follows a Q2 in which revenue grew 15.9% to $19.9M and the net loss narrowed to $3.2M, with $24.6M of cash and a stated 12-month runway. The company reiterated 2026 revenue guidance of $72M-$75M. The loss lands against a thin cash cushion, which makes the pace of AVISE CTD volume and reimbursement the swing factor for how long the runway holds. Insider activity has been mixed: CEO John Aballi sold 34,294 shares at $7.87 in October to cover taxes on vesting RSUs, while 10% owner Jorey Chernett bought 14,000 shares at a weighted average of $7.46.
At the time of this announcement, XGN was trading at $7.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $172M. The 52-week trading range was $2.59 to $10.41. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.